Should you stack peptides? What the evidence for each one covers, and does not

What 'stacking' actually means

Peptide stacking is the practice of combining two or more peptides on the theory that their effects add up or reinforce each other. A common version pairs a growth-hormone-releasing compound with a healing peptide and a metabolic peptide, taken on the same schedule with the goal of covering several outcomes at once.

The appeal is straightforward. If tesamorelin raises growth hormone, and BPC-157 is marketed for tissue repair, and MOTS-c is marketed for metabolic health, then combining all three sounds like a more complete intervention than any one alone. That logic treats each peptide as an independent module that can be added to a regimen without changing what the others do.

That assumption is the thing worth testing before anything else, because the individual evidence bases behind these molecules are not remotely equal to begin with, and no one has tested what happens when you put them together regardless.

Ranking the evidence, molecule by molecule

Lined up by strength of human evidence, the five peptides most often proposed for a stack fall into a steep ladder, from one real randomized trial in a specific patient population down to no human trials at all.

Tesamorelin sits at the top. It was tested in a multicentre randomized controlled trial in patients with HIV and excess visceral fat, a growth-hormone-releasing factor studied specifically for that population's abnormal fat accumulation.¹ That is a genuine clinical trial with a defined patient group, a defined comparator, and defined outcomes. It is also not a trial in healthy adults seeking body recomposition, and the metabolic profile of HIV-associated lipodystrophy is not the same starting point as an otherwise healthy person wanting to lose fat or build muscle.

CJC-1295 has one randomized study in healthy adults, showing prolonged stimulation of growth hormone and IGF-I secretion after dosing.² That is real human data, and it answers a real question: does the compound raise these hormones, and for how long. It does not answer whether raising them this way changes body composition, strength, recovery, or any outcome a person would actually notice. Hormone-level data is not clinical-outcome data, even when both come from a well-run study.

BPC-157 has almost no human evidence base to speak of. A 2026 review describes it plainly as an investigational peptide facing biopharmaceutical, formulation, and translational development barriers, which is a technical way of saying the drug-development groundwork required before human efficacy trials even make sense has not been completed.³ The animal literature on BPC-157 is large. The human trial literature is not.

TB-500 is sold under the promise of the healing properties associated with its parent protein, thymosin beta 4. The actual human trial evidence for thymosin beta 4 is a phase 2 randomized trial in people with severe dry eye, which showed improvement in signs and symptoms of that specific eye condition.⁴ That is a real randomized trial in real patients, and it is evidence for a topical ophthalmic application. It is not evidence for the systemic tissue-repair and recovery claims made for TB-500, which is a synthetic fragment sold in a different form for a different purpose than the molecule that was actually tested.

MOTS-c sits at the bottom with no human trials at all. The foundational paper shows that MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance, in mice and in cell systems.⁵ That is legitimate basic science describing a mitochondrial-derived peptide with a plausible metabolic role. It has not been given to a person in a published trial.

The central problem: zero combination trials

Set the individual evidence aside for a moment and look at what unites all five entries in that table: every study cited was a single-agent study. Nobody in the tesamorelin trial was also taking CJC-1295. Nobody in the thymosin beta 4 dry-eye trial was also taking MOTS-c. Each result belongs to one molecule, dosed alone, in one population.

That matters most on the growth hormone axis specifically, because it is a feedback system rather than a simple dial. Growth hormone secretion is regulated by releasing hormones, somatostatin, and downstream IGF-I feedback that suppresses further release when levels rise. Tesamorelin and CJC-1295 both act on this same axis through related mechanisms. Combining two agents that push on the same feedback loop from similar directions is not obviously additive, and it is not obviously safe, because nobody has measured what the combined secretory pattern, the downstream IGF-I response, or the feedback suppression looks like when both are present at once.

The honest description of a stack, then, is that it is a new, untested intervention, not a sum of previously tested ones. Each ingredient having its own study does not transfer safety or efficacy data to the combination. Pharmacology does not generally work by simple addition, and the growth hormone axis is a specific, well-documented example of a system with feedback loops that make combined dosing an open question rather than a reasonable extrapolation.

This is also true when the individual molecules are strong. If tesamorelin, with its genuine randomized trial, were stacked with CJC-1295, which also has real hormone-level data, the combination would still be untested. Good individual evidence does not average out to good combination evidence.

Regulatory status in the United States

Several of the peptides discussed here are not FDA-approved drugs, and several appear on FDA's bulk drug substances nominated for compounding lists, which is the mechanism FDA uses to evaluate whether a substance can lawfully be prepared by compounding pharmacies.⁶ Appearing on a nominated list is not the same as being approved for compounding, and it is not the same as being banned.

FDA's Pharmacy Compounding Advisory Committee reviewed several of these peptides in July 2026. PCAC is an advisory body. It makes recommendations to FDA; it does not itself issue rules, and no rule has been issued as a result of that meeting. Any claim that a specific peptide has been formally approved, banned, or given an availability timeline as a result of that meeting goes beyond what has been published.

What this means practically is that the regulatory status of individual stack components is unsettled and moving, and that unsettled status says nothing at all about whether combining them is safe or effective. Those are two separate open questions, and neither one resolves the other.

What a more rational approach looks like

None of this means every peptide on the list is equally unreasonable to consider. It means the reasonable approach treats each one according to its own evidence, in its own population, and refuses to borrow credibility from a neighbor on the same shelf.

Tesamorelin's trial data belongs to a specific clinical population with a specific metabolic abnormality. CJC-1295's data describes a hormone response, not an outcome. BPC-157 and MOTS-c are, at this point, research compounds without human trial support. TB-500's cited trial belongs to a different molecule and a different indication than the one it is sold to treat.

Adding these together into a stack multiplies uncertainty rather than dividing it. If you are drawn to the growth hormone axis specifically, because the biology of GH decline is real, there is a version of that intervention with an actual prescribing pathway and an actual clinician reviewing your labs: compounded sermorelin, a growth-hormone-releasing hormone analog that Astra prescribes through a state-licensed US compounding pharmacy after a clinical intake, not a self-assembled combination of research compounds ordered online.

Frequently asked questions

References

1. Human RCT Falutz J, Allas S, Blot K, et al.. “Metabolic effects of a growth hormone-releasing factor in patients with HIV” N Engl J Med, 2007.
2. Human RCT Teichman SL, Neale A, Lawrence B, et al.. “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults” J Clin Endocrinol Metab, 2006.
3. Review Mateescu DM, Gavrilescu DM, Constantinescu FE, et al.. “BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers” Pharmaceutics, 2026.
4. Human RCT Sosne G, Dunn SP, Kim C. “Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial” Cornea, 2015.
5. Animal study Lee C, Zeng J, Drew BG, et al.. “The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance” Cell Metab, 2015.
6. Reference US Food and Drug Administration. “Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act” FDA, 2026.